Alzheimer's disease, the undecided "one hundred years of solitude" has a new solution

Alzheimer's Disease (AD) is an irreversible degenerative disease of the cranial nerves, with about 40 million patients worldwide, and China accounts for about a quarter. Alzheimer's disease is a degenerative disease of the brain with progressive dementia as the main clinical manifestation, which is the most important cause of dementia in the elderly, so it is often commonly known as "Alzheimer's disease".

The exact cause and pathogenesis of Alzheimer's disease is not clear, from the perspective of the population, Alzheimer's disease often begins after the age of 50, and with age, its incidence has an increasing trend, up to 47% of people over 84 years old.

The onset of Alzheimer's disease is thought to involve deposition of β-amyloid (Abeta) and neural microtubule-binding protein tau, inflammatory response, genetic and cognitive impairment and other risk factors. Its underlying lesions are caused by the accumulation of plaques and tangles in specific parts of the brain tissue by Abeta and tau, and the production of Abeta is a key trigger for Alzheimer's disease.

In June this year, Simcere and Vivoryon Therapeutics reached a strategic regional licensing cooperation to develop and commercialize two neurotoxic amyloid N3pE (pGlu-Abeta) Alzheimer's disease treatment drugs in Greater China, including Varoglutamstat, becoming the first domestic enterprise to introduce an innovative AD drug pipeline.

Varoglutamstat, an oral small molecule inhibitor that targets glutamine peptide cyclase (QPCT), is one of the most promising therapies in the current development of AD drugs and is in clinical phase II.b development worldwide. Varoglutamstat inhibits the production of N3pE amyloid, which plays a role in the early stages of AD and triggers many pathological processes in AD, so Varoglutamstat has the potential to prevent neuronal damage.

Its pharmacological, toxicological, and major pharmacodynamic properties have been verified by preclinical studies, and the results of the short-term (12 weeks of treatment + 4 weeks of follow-up) efficacy of the completed phase IIa study show that Varoglutamstat has a significant statistical difference compared with placebo in a subscale representing working memory on the Neuropsychological Scale (Cogstate NTB). In addition, the results of varoglutamstat treatment were statistically significantly different from those of the control group in the suppression of QPCT enzymes in cerebrospinal fluid, Neurogranin in cerebrospinal fluid (a biomarker representing synaptic toxicity), YKL-40 (a biomarker representing neuroinflammation), and EEG

In 2020, the number of existing patients with Alzheimer's disease in China will be about 9 million, and it is predicted that it will grow to 21 million in 2050. The unmet clinical needs and social burden of Alzheimer's disease are increasing.

Because the early clinical manifestations of Alzheimer's disease are similar to the behavioral states manifested by aging, it is difficult to detect them early. After investigating the people with Alzheimer's disease, it was also found that many patients had reached the middle and late stages of their condition when they were diagnosed. Therefore, in daily life, we must do a good job of prevention, and we must understand more about the elderly at home and forget less.

The study of Alzheimer's disease is a road that stretches to the sky, and the way forward is coiled with unsolved life science fog, but it is closely related to us, because everyone will have physiological aging. Simcere Pharmaceutical is one of the many forwarders who have rushed into the fog, and for the first time, Alzheimer's disease drugs have been included in the research and development pipeline and quickly submitted clinical trial applications, hoping to let Alzheimer's patients use more effective drugs as soon as possible.

Source of the article: Simcere Pharmaceutical Public account

Image source: Baotu.com

Authorized.